查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511982

皮肤癌诊断市场规模、份额、趋势分析报告：按癌症类型、测试类型、最终用途、地区和细分市场预测，2024-2030 年

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Melanoma, Non-Melanoma), By Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

皮肤癌诊断市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球皮肤癌诊断市场规模将达到132.3亿美元，2024年至2030年复合年增长率为5.52%。

皮肤癌诊断市场由几个关键因素驱动。主要驱动因素是由于紫外线照射增加和人口老化导致皮肤癌发生率增加。人工智慧成像和分子诊断等诊断技术的进步将提高准确性和早期检测，进一步推动市场成长。提高认识宣传活动和促进早期筛检的政府倡议的增加也做出了重大贡献。此外，增加医疗成本和改善皮肤科护理对于扩大皮肤癌诊断市场至关重要。

在过去的十年中，黑色素瘤检测方法取得了重大进展，旨在减少黑色素瘤发病率和死亡率的增加。儘管有充分证据表明这些进步提高了黑色素瘤的早期检测率，但对其提高存活率的有效性仍存在相当大的批评。检测皮肤癌的传统方法通常涉及耗时且昂贵的程序，例如 PET 扫描和电脑断层扫描，以及使用射频波的侵入性技术。

该生物感测器于 2024 年 4 月在伦敦大学玛丽女王学院开发，提供了一种非侵入性且高效的解决方案。这种生物感测器利用太赫兹波的独特特性来侦测细胞特性的细微变化，太赫兹波的能量比X射线低，对人体更安全。此外，科学家们还开发了基因组测试，为肿瘤学家和皮肤科医生提供有关肿瘤分子生物学的宝贵资讯，特别是为侵袭性黑色素瘤和高危险鳞状细胞癌（SCC）患者提供。这些测试分析患者原发肿瘤的遗传讯息，并帮助更好地预测癌症在治疗后復发或扩散到身体其他部位的可能性。此外，这些测试提供了传统癌症分期无法提供的针对患者的见解。传统的癌症分期通常使用临床资讯和实验室报告与基于人群的资料进行比较来确定患者的预后。

在 COVID-19 时代，远距皮肤科变得越来越流行。这些用于皮肤癌诊断的新兴技术有可能整合到初级保健机构的远距皮肤病学。此外，将人工智慧与这些新技术结合可以进一步加速它们的采用。需要更大规模的多中心前瞻性临床试验，以确保这些新技术不会仅作为少数专门中心使用的实验设备。这可以透过维持每个国家的医疗保健提供者、一般民众、患者和医疗保健组织对此问题的认识来实现。

皮肤癌诊断市场报告亮点

  • 由于非黑色素瘤皮肤癌（NMSC）盛行率的上升以及用于诊断非黑色素瘤的新型诊断工具的开发，预计非黑色素瘤将在预测期内增长。
  • 从测试类型来看，皮肤切片检查占主导地位。皮肤切片检查在皮肤癌诊断中极为重要，是明确诊断的黄金标准。市场驱动因素包括患病率上升、切片检查技术的进步以及病理分析的改进。提高认识和筛检计划正在鼓励早期发现并推动对切片检查的需求。
  • 诊断成像领域预计在此期间将以更快的速度成长。皮肤癌发生率上升、诊断影像方法（皮肤镜检查、光同调断层扫瞄、共聚焦显微镜等）的技术进步以及早期检测意识的提高等因素都有助于市场扩张。此外，越来越多地采用非侵入性成像技术来提高准确性并减少患者不适，这进一步推动了市场的成长。
  • 医院和诊所领域在最终用途领域占据主导地位，预计在预测期内将以最快的速度成长。随着诊断采用的增加，医院也越来越接受它。医院实验室的发展对于满足患者不断变化的需求至关重要，越来越多的医院致力于在其环境中提供广泛的服务。
  • 由于主要企业的存在以及政府积极开发创新诊断工具等因素，北美在皮肤癌诊断市场占据主导地位。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章皮肤癌诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 皮肤癌诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章皮肤癌诊断市场：按癌症类型的估计和趋势分析

  • 全球皮肤癌诊断市场：按癌症类型分類的仪表板
  • 全球皮肤癌诊断市场：按癌症类型的波动分析
  • 全球皮肤癌诊断市场：按癌症类型和收益
  • 恶性黑色素瘤
  • 非黑色素瘤

第五章皮肤癌诊断市场：按测试类型估计和趋势分析

  • 全球皮肤癌诊断市场：按测试类型分類的仪表板
  • 全球皮肤癌诊断市场：依测试类型进行差异分析
  • 全球皮肤癌诊断市场：按测试类型和收益
  • 皮肤镜检查
  • 皮肤切片检查
  • 淋巴结活检
  • 影像检查
  • 其他的

第六章皮肤癌诊断市场：按测试类型估计和趋势分析

  • 全球皮肤癌诊断市场：按最终用途分類的仪表板
  • 全球皮肤癌诊断市场：最终用途的变异分析
  • 全球皮肤癌诊断市场：依最终用途、按收益
  • 医院和诊所
  • 研究机构
  • 其他的

第七章皮肤癌诊断市场：按癌症类型、测试类型和最终用途进行的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Castle Bioscience
    • DermTech
    • bioMerieux , Inc.
    • FOUNDATION MEDICINE, INC.
    • DermaSensor, Inc.
    • F . Hoffmann-La Roche Ltd
    • NeoGenomics Laboratories
    • Quest Diagnostics Incorporated
    • SkylineDx
    • Abbott
Product Code: GVR-4-68040-322-6

Skin Cancer Diagnostics Market Growth & Trends:

The global skin cancer diagnostics market size is anticipated to reach USD 13.23 billion by 2030 and is expected to expand at a CAGR of 5.52% from 2024 to 2030, according to a new report by Grand View Research, Inc. The skin cancer diagnostics market is driven by several key factors. Rising skin cancer incidence due to increased UV exposure and aging populations is a primary driver. Advances in diagnostic technologies, such as AI-powered imaging and molecular diagnostics, enhance accuracy and early detection, further propelling market growth. Increased awareness campaigns and government initiatives promoting early screening also contribute significantly. In addition, higher healthcare expenditures and improved access to dermatological care are crucial in expanding the skin cancer diagnostics market.

Over the past decade, significant advancements have been made in approaches to melanoma detection, all aimed at reducing the growing incidence of melanoma and its mortality rate. While these advancements have been well-documented to increase early melanoma detection, there has been considerable criticism of their efficacy in improving survival rates. Traditional methods for detecting skin cancer often involve time-consuming and expensive procedures, such as PET and CT scans, as well as invasive technologies using higher frequencies.

A biosensor developed at Queen Mary University of London in April 2024 offers a noninvasive and highly efficient solution. This biosensor leverages the unique properties of THz waves, which have lower energy than X-rays and are safe for humans, to detect subtle changes in cell characteristics. In addition, scientists have developed genomic tests that provide oncologists and dermatologists with valuable information about the molecular biology of tumors, particularly in patients with aggressive skin cancers such as invasive melanomas and high-risk Squamous Cell Carcinomas (SCCs). These tests analyze genetic information from a patient's primary tumor, helping physicians better forecast the likelihood of cancer recurrence after treatment and its potential spread to other parts of the body. Furthermore, these tests offer greater patient-specific insights that are not available through traditional cancer staging, which typically uses clinical information and lab reports compared with population-based data to determine a patient's prognosis.

In the era of COVID-19, teledermatology has become increasingly popular. These emerging techniques for skin cancer diagnosis have the potential to be integrated into teledermatology in primary care settings. Furthermore, combining AI with these emerging techniques can further enhance their widespread use. More large-scale, multicenter, prospective clinical trials are needed to prevent these emerging techniques from remaining experimental equipment used in only a few special centers. This can be achieved by maintaining interest in this issue among health providers, the general population, patients, and health-related organizations in each country.

Skin Cancer Diagnostics Market Report Highlights:

  • Nonmelanoma dominated the cancer type segment and is anticipated to grow at fastest growth rate over the forecast period owing to the owing to the rising incidence of Nonmelanoma Skin Cancer (NMSC) and development of novel diagnostics tools for the diagnosis of no melanoma cancer
  • Skin biopsy dominated the test type segment. Skin biopsies are pivotal in skin cancer diagnostics, serving as the gold standard for definitive diagnosis. Market driving factors include the rising prevalence, advancements in biopsy techniques, and improved pathological analysis. Increased awareness and screening programs promote early detection, boosting biopsy demand
  • Imaging segment is expected to grow at faster rate during the review period. Factors such as the rising incidence of skin cancer, technological advancements in imaging modalities (like dermoscopy, optical coherence tomography, and reflectance confocal microscopy), and increasing awareness about early detection contribute to market expansion. Additionally, the growing adoption of non-invasive imaging techniques, which offer improved accuracy and reduced patient discomfort, further propel market growth
  • Hospitals and clinics segment dominated the end-use segment and is anticipated to grow at fastest growth rate over the forecast period. As diagnostics are being increasingly adopted, their acceptance has increased in hospitals as well. Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals are aiming to provide a wide range of services in their settings
  • North America dominated the skin cancer diagnostics market owing to factors such as the presence of major key players, favorable government initiatives for the development of innovative diagnostics tools

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer Type
    • 1.2.2. Test Type
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research End-use
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer Type and test type outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Integration of artificial intelligence
      • 3.2.1.3. Patient preference for non-invasive diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic Imaging
  • 3.3. Skin Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
  • 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
  • 4.4. Melanoma
    • 4.4.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-Melanoma
    • 4.5.1. Non-Melanoma market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
  • 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
  • 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
  • 5.4. Dermatoscopy
    • 5.4.1. Dermatoscopy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Skin Biopsy
    • 5.5.1. Skin Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Lymph node biopsy
    • 5.6.1. Lymph node biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Imaging Tests
    • 5.7.1. Imaging Tests market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 6.1. Global Skin Cancer Diagnostics Market: End-use Dashboard
  • 6.2. Global Skin Cancer Diagnostics Market: End-use Movement Analysis
  • 6.3. Global Skin Cancer Diagnostics Market by End-use, Revenue
  • 6.4. Hospital and Clinics
    • 6.4.1. Hospital and Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Laboratories
    • 6.5.1. Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Analysis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type and End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Castle Bioscience
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. DermTech
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. bioMerieux , Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. FOUNDATION MEDICINE, INC.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DermaSensor, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F . Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. NeoGenomics Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quest Diagnostics Incorporated
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. SkylineDx
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abbott
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 4 North America skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 5 North America skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 7 U.S. skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 U.S. skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 10 Canada skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 11 Canada skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 14 Europe skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 Europe skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Germany skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 17 Germany skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 18 Germany skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 20 UK skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 UK skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 23 France skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 24 France skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 26 Italy skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Italy skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 29 Spain skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Spain skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Denmark skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 32 Denmark skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 33 Denmark skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Sweden skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 35 Sweden skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 Sweden skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Norway skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 38 Norway skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 39 Norway skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 China skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 45 China skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 46 China skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 48 Japan skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Japan skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 51 India skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 52 India skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 54 South Korea skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 55 South Korea skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 57 Australia skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Australia skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 60 Thailand skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 61 Thailand skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 64 Latin America skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 65 Latin America skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 67 Brazil skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 68 Brazil skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 70 Mexico skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 71 Mexico skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 73 Argentina skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 74 Argentina skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 MEA skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 77 MEA skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 78 MEA skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 80 South Africa skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 81 South Africa skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 86 UAE skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 87 UAE skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Skin cancer diagnostics market: market outlook
  • Fig. 14 Skin cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Skin cancer diagnostics market driver impact
  • Fig. 18 Skin cancer diagnostics market restraint impact
  • Fig. 19 Skin cancer diagnostics market: Cancer Type movement analysis
  • Fig. 20 Skin cancer diagnostics market: Cancer Type outlook and key takeaways
  • Fig. 21 Melanoma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Non-Melanoma estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Skin cancer diagnostics market: Test Type movement analysis
  • Fig. 24 Skin cancer diagnostics market: Test Type outlook and key takeaways
  • Fig. 25 Dermatoscopy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Skin biopsy estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Lymph node biopsy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Imaging tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Skin cancer diagnostics market: End-use movement analysis
  • Fig. 31 Skin cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 32 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Laboratories estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Global skin cancer diagnostics market: Regional movement analysis
  • Fig. 36 Global skin cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 37 Global skin cancer diagnostics market share and leading players
  • Fig. 38 North America, by country
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Market share of key market players - Skin cancer diagnostics market